328 related articles for article (PubMed ID: 8849454)
41. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
[TBL] [Abstract][Full Text] [Related]
42. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
43. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.
Alfonso C; Liljedahl M; Winqvist O; Surh CD; Peterson PA; Fung-Leung WP; Karlsson L
Immunol Rev; 1999 Dec; 172():255-66. PubMed ID: 10631951
[TBL] [Abstract][Full Text] [Related]
44. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM.
Robbins NF; Hammond C; Denzin LK; Pan M; Cresswell P
Hum Immunol; 1996 Jan; 45(1):13-23. PubMed ID: 8655355
[TBL] [Abstract][Full Text] [Related]
45. What to do with HLA-DO/H-2O two decades later?
Welsh R; Song N; Sadegh-Nasseri S
Immunogenetics; 2019 Mar; 71(3):189-196. PubMed ID: 30683973
[TBL] [Abstract][Full Text] [Related]
46. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
47. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
48. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
49. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
50. Functional HLA-DM on the surface of B cells and immature dendritic cells.
Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
[TBL] [Abstract][Full Text] [Related]
51. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
Chou CL; Sadegh-Nasseri S
J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
[TBL] [Abstract][Full Text] [Related]
52. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
Ullrich HJ; Döring K; Grüneberg U; Jähnig F; Trowsdale J; van Ham SM
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13163-8. PubMed ID: 9371817
[TBL] [Abstract][Full Text] [Related]
53. Out damned CLIP! Out, I say!
Roche PA
Science; 1996 Oct; 274(5287):526-7. PubMed ID: 8928005
[No Abstract] [Full Text] [Related]
54. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
[TBL] [Abstract][Full Text] [Related]
55. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.
Fling SP; Rak J; Muczynski KA; Arp B; Pious D
J Exp Med; 1997 Nov; 186(9):1469-80. PubMed ID: 9348304
[TBL] [Abstract][Full Text] [Related]
56. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
Vogt AB; Kropshofer H; Hämmerling GJ
Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
[TBL] [Abstract][Full Text] [Related]
57. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
58. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
59. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway.
Schulze MS; Wucherpfennig KW
Curr Opin Immunol; 2012 Feb; 24(1):105-11. PubMed ID: 22138314
[TBL] [Abstract][Full Text] [Related]
60. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
